New York Attorney General Files Antitrust Lawsuit To Block Discontinuation Of Sales Of Branded Alzheimer’s Treatment Drug

On September 16, 2014, the New York Attorney General’s (AG) Office announced it had filed a federal antitrust lawsuit against Actavis plc (the new owner of Forest Laboratories, Inc.) to prevent them from discontinuing sales of Namenda, a medication used to slow progress of Alzheimer’s disease, and shifting users to a newer patented version of the drug. The basis of the lawsuit is in response to the June 2014 announcement by Forest Laboratories of its plans to market Namenda tablets (5 mg and 10 mg) into the fall of 2014 and focus on  “converting” consumers taking the tablets . . .